A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Status:
Completed
Trial end date:
2019-08-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of siltuximab compared with
placebo (an inactive substance that is compared with a drug to test whether the drug has a
real effect in a clinical trial) in patients with high-risk smoldering multiple myeloma
(SMM).